ADA-friendly PDF: An Heir Apparent for Statins? PCSK9 Inhibitors Dramatically Reduce LDL-C Levels

An Heir Apparent for Statins? PCSK9 Inhibitors Dramatically Reduce LDL-C Levels

Statins can lower low-density lipoprotein cholesterol (LDL-C) levels from 25% to 50% but for many patients that is not enough to reach target levels, leaving them at residual risk for cardiovascular events. Some patients experience muscle aches when taking statins and must discontinue therapy or take suboptimal dose.

More at Progressnotes, MUSC’s Medical Magazine